fda bpc-157 compounding category 2 list Approval Status 2026: Clinical Trials FDA has removed certain bulk
FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Panel to Review 7 Peptides in July (2026) Big news for the peptide space., The FDA Pharmacy Compounding Advisory Committee recently voted eight to six in favor of allowing compounding pharmacies to produce BPC 157. Here is what you need to BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA advisory committee votes to add popular peptide BPC 157 to drug compounding list AOL The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step
Pay in 4 interest-free payments of $7.42 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
